Poster & Publications

Circulating H3K27 nucleosomes to monitor lung cancer patients during treatment

April 19, 2023

Share
Tweet
Share on Facebook
Share

Paper titled: Circulating H3K27 Nucleosomes to monitor Lung Cancer Patients During Treatment, a universal biomarker quantifiying the minimal residual disease (MRD) in plasma samples.

Grolleau et al 2023

Presented at AACCR 2023

Download

Poster & Publications
Circulating H3K27me3 modified nucleosomes as a biomarker to monitor anti EZH2-based treatment in advanced solid tumour patients
Poster & Publications
Novel ctDNA technology for early cancer detection by immunoprecipitation of tumor associated ctDNA fragments and analysis by qPCR

Share
Tweet
Share on Facebook
Share

Subscribe for Volition product updates.

Or, click here for Investor Updates and press releases.

"*" indicates required fields

Receive product updates for:

Animal Health

Human Health

Name

First Name Last Name

Company Name*

Your Email Address*

CAPTCHA

Circulating H3K27 nucleosomes to monitor lung cancer patients during treatment

Related Articles

Circulating H3K27me3 modified nucleosomes as a biomarker to monitor anti EZH2-based treatment in advanced solid tumour patients

Novel ctDNA technology for early cancer detection by immunoprecipitation of tumor associated ctDNA fragments and analysis by qPCR

Subscribe for Volition product updates.

Or, click here for Investor Updates and press releases.

Contact